Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Hairgenetix Copper Peptide Serum and PeptideLabz GHK-Cu + AHK-Cu Serum are being compared for effectiveness in hair loss treatment. The user is seeking recommendations for other brands with authentic reviews.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.